Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis. 1985

N Väätäinen, and A Hollmen, and J E Fräki

Twenty five patients with severe and extensive psoriasis were treated with trimethylpsoralen (trioxsalen) bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (Ro 10-9359). Etretinate was started (1 mg/kg/day) 2 weeks prior to starting the bath PUVA treatment daily. Psoriasis cleared with fifteen treatments in 96% of patients with a mean total UVA dose of 3.9 joules/cm2. The control group of nine patients received only bath PUVA without retinoid, and eight of them cleared with nineteen treatments and with a mean UVA dose of 7.2 joules/cm2. In addition, three psoriatic patients previously resistant to bath PUVA treatment were given etretinate (1 mg/kg/day), and they cleared in 4 to 8 weeks after starting etretinate with a UVA dose of 37-144 joules/cm2. In the maintenance therapy after the combination therapy of twenty-four patients, the results of treatment were good or excellent in fourteen of fifteen patients (93%) getting only bath PUVA one to two times a week and in four of nine patients (44%) getting etretinate (25-50 mg daily) in a mean follow-up time of 10 weeks. These results show the benefits of the combination of trimethylpsoralen bath PUVA with an oral retinoid, etretinate, in the treatment of severe and extensive psoriasis.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010778 Photochemotherapy Therapy using oral or topical photosensitizing agents with subsequent exposure to light. Blue Light Photodynamic Therapy,Photodynamic Therapy,Red Light PDT,Red Light Photodynamic Therapy,Therapy, Photodynamic,Light PDT, Red,PDT, Red Light,Photochemotherapies,Photodynamic Therapies,Therapies, Photodynamic
D011564 Furocoumarins Polycyclic compounds consisting of a furan ring fused with coumarin. They commonly occur in PLANTS, especially UMBELLIFERAE and RUTACEAE, as well as PSORALEA. Furanocoumarin,Furanocoumarins,Furocoumarin,Psoralens,Angelicins
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D011701 PUVA Therapy Photochemotherapy using PSORALENS as the photosensitizing agent and ultraviolet light type A (UVA). Psoralen Ultraviolet A Therapy,Therapy, PUVA,PUVA Therapies,Therapies, PUVA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005050 Etretinate An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic. B10-9359,Ethyl Etrinoate,Ro 10-9359,Ro-10-9359,Tigason,Tigazon,B10 9359,B109359,Etrinoate, Ethyl,Ro 10 9359,Ro 109359,Ro109359
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

N Väätäinen, and A Hollmen, and J E Fräki
January 1982, The British journal of dermatology,
N Väätäinen, and A Hollmen, and J E Fräki
January 1984, Revista medica de Chile,
N Väätäinen, and A Hollmen, and J E Fräki
October 1984, Ethiopian medical journal,
N Väätäinen, and A Hollmen, and J E Fräki
August 1978, The British journal of dermatology,
N Väätäinen, and A Hollmen, and J E Fräki
March 2001, The British journal of dermatology,
N Väätäinen, and A Hollmen, and J E Fräki
January 1978, Dermatologica,
N Väätäinen, and A Hollmen, and J E Fräki
August 1988, Journal of the American Academy of Dermatology,
N Väätäinen, and A Hollmen, and J E Fräki
January 2015, The British journal of dermatology,
N Väätäinen, and A Hollmen, and J E Fräki
April 1986, Geburtshilfe und Frauenheilkunde,
N Väätäinen, and A Hollmen, and J E Fräki
January 2004, Acta dermato-venereologica,
Copied contents to your clipboard!